US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Drug Discovery: market research reports

RSS Feeds

Drug Discovery market research reports and industry analysis

1    3    5  6  7  8  9  10  
Brain Cancer Drug Pathway Analyzer 2014
7/15/2014 | published by: BioSeeker Group AB
... intracellular signaling pathways for the treatment of brain cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 188 drug targets that are included in this drug-pathway analyzing ...  |  read more...
USD 6,746
Cytokine Therapy in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... accumulated number of ceased drugs over the last years amount to another 8 drugs. Cytokine Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ...  |  read more...
USD 4,496
EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 312 drugs. Egfr1 Signaling Pathway In Oncology Drug Pipeline Update lists ...  |  read more...
USD 6,746
ErbB Signaling Pathway in Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces ...  |  read more...
USD 6,746
Hematological Cancers Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... 765 hematological cancer drugs in 1629 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 230 drugs. Hematological Cancers ...  |  read more...
USD 8,996
Targeting Tight Junctions in Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... consisting of many different proteins that form large complexes. There are today 89 companies plus partners developing 89 tight junction targeting drugs in 336 developmental projects in cancer. In addition, there is 1 suspended drug ...  |  read more...
USD 4,496
Biologicals in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... developing 1686 biological drugs in 3815 developmental projects in cancer. In addition, there are 28 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 932 drugs. Biologicals In ...  |  read more...
USD 11,246
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... three successful drugs are just the top of an emerging line of therapy. Given the fact that they all target tyrosine kinases and that kinase mutations can cause patients to become resistant to these drugs, ...  |  read more...
USD 6,746
Bladder Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... treated early, the 5 year survival rate is 94%. There are today 102 companies plus partners developing 123 drugs targeting bladder cancer in development. In addition, there are 3 suspended drugs and the accumulated number ...  |  read more...
USD 4,496
Hematological Cancers Drug Pathway Analyzer 2014
7/15/2014 | published by: BioSeeker Group AB
... intracellular signaling pathways for the treatment of hematological cancers. The rational for this plethora of treatment strategies is based on our increasing understanding of the 356 drug targets that are included in this drug-pathway analyzing ...  |  read more...
USD 6,746
TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... in 1411 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 227 drugs. Tgf-Beta Receptor Signaling Pathway In Oncology ...  |  read more...
USD 6,746
Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... as homologs of Toll in Drosophila. Mammalian TLRs are expressed on innate immune cells, such as macrophages and dendritic cells, and respond to the membrane components of Gram-positive or Gram-negative bacteria. Pathogen recognition by TLRs ...  |  read more...
USD 6,746
TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... in 2048 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 257 drugs. Tnf-Alpha Signaling Pathway In Oncology Drug ...  |  read more...
USD 6,746
IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 27 drugs. Il-7 Signaling Pathway In Oncology Drug Pipeline Update lists ...  |  read more...
USD 2,246
mTOR Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... several hallmarks of cancer such as cell growth and proliferation, angiogenesis, and bioenergetics. Since mTOR acts as a neoplastic switch that is frequently turned on by many mutations found in cancer, inhibition of mTOR may ...  |  read more...
USD 6,746
Colorectal Cancer Drug Pathway Analyzer 2014
7/15/2014 | published by: BioSeeker Group AB
... intracellular signaling pathways for the treatment of colorectal cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 253 drug targets that are included in this drug-pathway analyzing ...  |  read more...
USD 6,746
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H2 2014
7/15/2014 | published by: Global Markets Direct
... report provides comprehensive information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule ...  |  read more...
USD 2,000
Epithelial Ovarian Cancer - Pipeline Review, H2 2014
7/15/2014 | published by: Global Markets Direct
... information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest ...  |  read more...
USD 2,000
Chronic Heart Failure - Pipeline Review, H2 2014
7/15/2014 | published by: Global Markets Direct
... information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest ...  |  read more...
USD 2,000
Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2014
7/15/2014 | published by: Global Markets Direct
... report provides comprehensive information on the therapeutic development for Spinal Muscular Atrophy (SMA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule ...  |  read more...
USD 2,000
Open-Angle Glaucoma - Pipeline Review, H2 2014
7/15/2014 | published by: Global Markets Direct
... therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2014
7/15/2014 | published by: Global Markets Direct
... report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule ...  |  read more...
USD 2,000
Brain Tumor - Pipeline Review, H2 2014
7/15/2014 | published by: Global Markets Direct
... therapeutic development for Brain Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Neurofibromatoses Type II - Pipeline Review, H2 2014
7/15/2014 | published by: Global Markets Direct
... information on the therapeutic development for Neurofibromatoses Type II, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest ...  |  read more...
USD 2,000
Anaplastic Astrocytoma - Pipeline Review, H2 2014
7/15/2014 | published by: Global Markets Direct
... therapeutic development for Anaplastic Astrocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
1    3    5  6  7  8  9  10